FRESENIUS KABI INDIA PVT LTD

Pune-based Fresenius Kabi India, a 100 per cent subsidiary of Fresenius Kabi AG Germany, recorded a revenue of Rs 205 crore in the biopharma space during FY 20-21, exhibiting a growth of 12 per cent when compared to the revenue generation in FY 19-20 recorded at Rs 182 crore. Established in 1995, Fresenius Kabi India deals in clinical nutrition; IV drugs which formulate intravenously administered generic drugs such as oncology drugs, anesthetics & analgesics, anti-infective & critical care drugs. The portfolio also includes infusion therapy.